Abstract
Purpose Non-pharmaceutical interventions (NPIs) have been the cornerstone of COVID-19 pandemic control, but evidence on their effectiveness varies according to the methods and approaches taken to empirical analysis.
We analysed the impact of NPIs on incident SARS-CoV-2 across 32 European countries (March-December 2020) using two NPI trackers: the Corona Virus Pandemic Policy Monitor – COV-PPM, and the Oxford Covid-19 Government Response Tracker – OxCGRT.
Methods NPIs were summarized through principal component analysis into three sets, stratified by two waves (C1-C3, weeks 5-25, and C4-C6, weeks 35-52). Longitudinal, multi-level mixed-effects negative binomial regression models were fitted to estimate incidence rate ratios for cases and deaths considering different time-lags and reverse causation (i.e. changing incidence causing NPIs), stratified by waves and geographical regions (Western, Eastern, Northern, Southern, Others).
Results During the first wave, restrictions on movement/mobility, public transport, public events, and public spaces (C1) and healthcare system improvements, border closures and restrictions to public institutions (C2) reduced SARS-CoV-2 incidence after 28 and 35-days. Mask policies (C3) reduced SARS-CoV-2 incidence (except after 35-days). During wave 1, C1 and C2 reduced deaths after 49-days and C3 after 21, 28 and 35-days. During wave 2, restrictions on movement/mobility, public transport and healthcare system improvements (C5) decreased SARS-CoV-2 cases and deaths across all countries.
Conclusion In the absence of pre-existing immunity, vaccines or treatment options, the impact of NPIs on SARS-CoV-2 incidence and deaths varied by regions and waves but was consistent across components of NPIs derived from two policy trackers (CoV-PPM and OxCGRT).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received funds from the Federal Ministry of Health Germany (Bundesministerium fur Gesundheit, ZMVI1 2520COR410).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The information gathered and analysed was retrieved from public official websites across Europe and from freely available datasets. The NPIs database used can be accessed at https://doi.org/10.7910/DVN/ANTOH7. SARS-Cov-2 infection cases and deaths was retrieved from the public WHO online platform: https://covid19.who.int/data. No ethical clearance was required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The updated version of the manuscript contains a systematic comparison between NPI effects on COVID-19 incidence and associated deaths using two NPI trackers.
Data Availability
The information gathered and analysed was retrieved from public official websites across Europe and from freely available datasets. The NPIs database used can be accessed at https://doi.org/10.7910/DVN/ANTOH7. SARS-Cov-2 infection cases and deaths was retrieved from the public WHO online platform: https://covid19.who.int/data.
